Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes

Devenir au Long Cours de la Cellule bêta Chez Les Adultes Porteurs d'Anomalies génétiques à l'Origine du Diabète Néonatal

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02072551

Acronym

GLUCONEO

Enrollment

Registered

2014-02-26

Start date

2012-12-31

Completion date

2016-12-31

Last updated

2016-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The main objective of this study is to evaluate Beta cells in patients with a neonotal diabetes linked to a genetic abnormality Metabolic caracteristics will described using a transversal cohort study.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Age : 18 à 65 year * diabetic patient with a neonatal diabetis (before 1 year old) and need for insuline or patient with a relative having neonatal diabetis

Exclusion criteria

Diabète induit (médicaments - ex corticoïdes) ou syndromique * infection * cancer * pegnancy

Design outcomes

Primary

Measure	Time frame
Mean insulin secretion output	Week after inclusion

Secondary

Measure	Time frame
insulin secretion outout after arginine perfusion	during hospitalisation (3 days)
sensitivity to insulin	during hospitalisation (3 days)
glucago secretion output	during hospitalisation (3 days)

Countries

France

Outcome results